Artemisinin - CAS 63968-64-9
Catalog number:
63968-64-9
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C15H22O5
Molecular Weight:
282.33
COA:
Inquire
Targets:
HCV
Description:
Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial.
Grigg MJ1, William T2, Menon J3, Barber BE1, Wilkes CS1, Rajahram GS4, Edstein MD5, Auburn S6, Price RN7, Yeo TW8, Anstey NM9. Clin Infect Dis. 2016 Apr 22. pii: ciw121. [Epub ahead of print]
BACKGROUND:  Chloroquine (CQ)-resistant Plasmodium vivax is increasingly reported throughout southeast Asia. The efficacy of CQ and alternative artemisinin combination therapies (ACTs) for vivax malaria in Malaysia is unknown.
2.Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling.
Tong Y1,2, Liu Y1,2, Zheng H2, Zheng L1,2, Liu W1,2, Wu J2, Ou R2, Zhang G2, Li F2, Hu M2,3, Liu Z1,2, Lu L2. Oncotarget. 2016 Apr 22. doi: 10.18632/oncotarget.8920. [Epub ahead of print]
Non-small-cell lung cancer (NSCLC) is the most prevalent malignancy worldwide given its high incidence, considerable mortality, and poor prognosis. The anti-malaria compounds artemisinin (ART), dihydroartemisinin (DHA), and artesunate (ARTS) reportedly have anti-cancer potential, although the underlying mechanisms remain unclear. In this work, we used flow cytometry to show that ART, DHA, and ARTS could inhibit the proliferation of A549 and H1299 cells by arresting cell cycle in G1 phase. Meanwhile, tumor malignancy including migration, invasion, cancer stem cells, and epithelial-mesenchymal transition were also significantly suppressed by these compounds. Furthermore, ART, DHA, and ARTS remarkably decreased tumor growth in vivo. By using IWP-2, the inhibitor of Wnt/β-catenin pathway, and Wnt5a siRNA, we found that ART, DHA, and ARTS could render tumor inhibition partially dependent on Wnt/β-catenin inactivation. These compounds could strikingly decrease the protein level of Wnt5-a/b and simultaneously increase those of NKD2 and Axin2, ultimately resulting in β-catenin downregulation.
3.Artesunate inhibits adipogeneis in 3T3-L1 preadipocytes by reducing the expression and/or phosphorylation levels of C/EBP-α, PPAR-γ, FAS, perilipin A, and STAT-3.
Jang BC1. Biochem Biophys Res Commun. 2016 Apr 21. pii: S0006-291X(16)30614-3. doi: 10.1016/j.bbrc.2016.04.109. [Epub ahead of print]
Differentiation of preadipocyte, also called adipogenesis, leads to the phenotype of mature adipocyte. However, excessive adipogenesis is closely linked to the development of obesity. Artesunate, one of artemisinin-type sesquiterpene lactones from Artemisia annua L., is known for anti-malarial and anti-cancerous activities. In this study, we investigated the effect of artesunate on adipogenesis in 3T3-L1 preadipocytes. Artesunate strongly inhibited lipid accumulation and triglyceride (TG) synthesis during the differentiation of 3T3-L1 preadipocytes into adipocytes at 5 μM concentration. Artesunate at 5 μM also reduced not only the expressions of CCAAT/enhancer-binding protein-α (C/EBP-α), peroxisome proliferator-activated receptor-γ (PPAR-γ), fatty acid synthase (FAS), and perilipin A but also the phosphorylation levels of signal transducer and activator of transcription-3 (STAT-3) during adipocyte differentiation. Moreover, artesunate at 5 μM reduced leptin, but not adiponectin, mRNA expression during adipocyte differentiation.
4.Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling.
Tong Y1,2, Liu Y1,2, Zheng H2, Zheng L1,2, Liu W1,2, Wu J2, Ou R2, Zhang G2, Li F2, Hu M2,3, Liu Z1,2, Lu L2. Oncotarget. 2016 Apr 22. doi: 10.18632/oncotarget.8920. [Epub ahead of print]
Non-small-cell lung cancer (NSCLC) is the most prevalent malignancy worldwide given its high incidence, considerable mortality, and poor prognosis. The anti-malaria compounds artemisinin (ART), dihydroartemisinin (DHA), and artesunate (ARTS) reportedly have anti-cancer potential, although the underlying mechanisms remain unclear. In this work, we used flow cytometry to show that ART, DHA, and ARTS could inhibit the proliferation of A549 and H1299 cells by arresting cell cycle in G1 phase. Meanwhile, tumor malignancy including migration, invasion, cancer stem cells, and epithelial-mesenchymal transition were also significantly suppressed by these compounds. Furthermore, ART, DHA, and ARTS remarkably decreased tumor growth in vivo. By using IWP-2, the inhibitor of Wnt/β-catenin pathway, and Wnt5a siRNA, we found that ART, DHA, and ARTS could render tumor inhibition partially dependent on Wnt/β-catenin inactivation. These compounds could strikingly decrease the protein level of Wnt5-a/b and simultaneously increase those of NKD2 and Axin2, ultimately resulting in β-catenin downregulation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HCV Products


CAS 1206524-86-8 MK-5172 potassium salt

MK-5172 potassium salt
(CAS: 1206524-86-8)

In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical stu...

GSK-2818713

GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex i...

Ravidasvir HCl
(CAS: 1303533-81-4)

Avidasvir is a second-generation Hepatitis C virus NS 5 protein inhibitor. In Sep 2016, Phase-II/III clinical trials in Hepatitis C in Malaysia was on-going.

CAS 1502655-48-2 Ledipasvir diacetone

Ledipasvir diacetone
(CAS: 1502655-48-2)

Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.0...

Ombitasvir
(CAS: 1258226-87-7)

Ombitasvir, a NS5A inhibitor, could be effective in the treatment of HCV as an antiviral agent. IC50: 14 pM and 5 pM (EC50) for genotype 1a-H77 and 1b-Con1 resp...

CAS 923604-59-5 Simeprevir

Simeprevir
(CAS: 923604-59-5)

Simeprevir plays an important role in HCV replication. Data from phase I and II clinical trials of TMC-435350 (TMC 435350; TMC 435; TMC-435350) to date have sho...

CAS 876708-03-1 RO-9187

RO-9187
(CAS: 876708-03-1)

RO-9187 is a potent inhibitor of HCV virus replication in the replicon system. It is excellent substrates for deoxycytidine kinase and were phosphorylated with ...

CAS 630420-16-5 Asunaprevir

Asunaprevir
(CAS: 630420-16-5)

Asunaprevir is a potent hepatitis C virus (HCV) non-structural protein protease inhibitor currently in Phase III clinical trials for the treatment of HCV infect...

CAS 1190308-01-0 PSI-7976

PSI-7976
(CAS: 1190308-01-0)

PSI-7976 is an inhibitor of HCV RNA replication with EC50 value of 1.07μM. PSI-7851 is a phosphoramidate prodrug of PSI-7411 and has potent anti-hepatitis C vir...

CAS 1350514-68-9 MK-5172

MK-5172
(CAS: 1350514-68-9)

In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical stu...

CAS 1015073-42-3 PSI-7409

PSI-7409
(CAS: 1015073-42-3)

PSI-7409, the active 5′-triphosphate metabolite of PSI-7851, is a potent inhibitor of the HCV NS5B RNA dependent RNA polymerase.

CAS 1256388-51-8 Ledipasvir

Ledipasvir
(CAS: 1256388-51-8)

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

ACH-806
(CAS: 870142-71-5)

ACH-806 is a Hepatitis C virus NS3 protein inhibitor. It can inhibit viral RNA replication in HCV replicon cells and is active in genotype 1 HCV-infected patien...

CAS 1026785-59-0 VX-222 (VCH-222, Lomibuvir)

VX-222 (VCH-222, Lomibuvir)
(CAS: 1026785-59-0)

VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold ...

CAS 1441674-54-9 Ledipasvir acetone

Ledipasvir acetone
(CAS: 1441674-54-9)

Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.0...

CAS 394730-60-0 Boceprevir

Boceprevir
(CAS: 394730-60-0)

An NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.

CAS 863329-66-2 PSI-6206

PSI-6206
(CAS: 863329-66-2)

PSI-6206 (RO2433) is a selective HCV RNA polymerase inhibitor. It is the unphosphorylated parent compound of triphosphate analog PSI-7409, which is a potent inh...

APC-6336
(CAS: 263870-19-5)

APC-6336 is a Hepatitis C virus NS3 protein inhibitor.

CAS 1009119-64-5 Daclatasvir

Daclatasvir
(CAS: 1009119-64-5)

Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).

CAS 958002-33-0 Beclabuvir

Beclabuvir
(CAS: 958002-33-0)

Beclabuvir is a potent, non-nucleotide inhibitor of HCV NS5B which is currently in Phase III clinical trials for the treatment of chronic HCV infection. Beclabu...

Chemical Structure

CAS 63968-64-9 Artemisinin

Quick Inquiry

Verification code

Featured Items